Feature | August 27, 2012

Varian Offers Professional RT Training in Brazil

The company launches software in Portuguese and invests in online course of the Brazilian Society of Radiotherapy to increase the accessibility and quality of radiation therapy treatment in Brazil

Stock image

August 27, 2012 — Varian Medical Systems, a manufacturer of technology for the treatment of cancer with radiotherapy and radiosurgery, has launched Portuguese versions of its software systems for planning and managing radiotherapy treatments. Varian personnel worked with Brazilian cancer treatment specialists to translate its software products into Portuguese and also to adapt them so that they facilitate Brazilian treatment practices, in order to support the safe and effective use of radiotherapy in the country.

"We felt this was a very important step to take, in order to support Brazilian professionals who need to use radiotherapy technology but may not speak fluent English," said Kolleen Kennedy, president of Varian's Oncology Systems business.   

Radiotherapy is indicated for more than 60 percent of all cancer cases, including the most prevalent in the Brazilian population: prostate and lung cancer among men, and breast and cervical cancer among women. Modern radiotherapy requires development of a complex treatment plan, using software programs such as Varian's Eclipse (for treatment planning) and Aria (for managing all aspects of treatment).

Varian is also expanding its investment in radiotherapy training for Brazilian specialists. The company signed an agreement with Capes (Federal Agency of Support and Evaluation of Postgraduate Education) for investments in the Science Without Borders program, an initiative of the federal government to promote the consolidation, expansion and internationalization of science, technology and innovation through the exchange and the international mobility of students and researchers. In addition, through the Varian Foundation, it will provide financial resources for implementing an ongoing distance education program being created by the Brazilian Society of Radiotherapy (SBRT) to update professionals around the country. The SBRT will choose the faculty for this distance learning series. Classes will be transmitted through a virtual platform hosted on the site of SBRT.

"The goal of this online course is to bring knowledge of new technologies to professionals in areas that are remote from major centers, enabling them to make better treatment decisions in accordance with current technological capabilities. This will improve the level of radiotherapy expertise in the country and will have direct impact on patient access to more advanced treatments in these regions, effectively delivered by professionals with the proper skill levels," says Dr. Robson Ferrigno, president of SBRT.

Varian in Brazil

Varian has had a long and productive relationship with Brazil's cancer treatment community, having supplied the country's first linear accelerator to Hospital Oswaldo Cruz in 1971. 

Currently, Varian technology is deployed at many of Brazil's preeminent cancer treatment institutions including the National Cancer Institute (INCA) in Rio de Janeiro, Hospital Israelita Albert Einstein, Hospital AC Camargo and Hospital Sirio Libanes, in Sao Paulo.

The company currently has an office in Sao Paulo, with nearly 60 Brazilian employees.

For more information, visit www.varian.com

 

Related Content

Results of Journal of the American College of Surgeons study should reassure breast cancer patients who experienced surgical postponements due to COVID-19 pandemic

Association between Time to Operation and Pathological Stage in DCIS & ER+ Breast Cancer. Courtesy of American College of Surgeons

News | Women's Health | August 07, 2020
August 7, 2020 — A new br...

An oncologist practices social distancing while talking to a cancer patient. Image courtesy of University of Michigan Rogel Cancer Center

News | Coronavirus (COVID-19) | August 07, 2020
August 7, 2020 — When COVID-19 struck, health ca
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
According to the new market research report "Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) - Global Forecast to 2025", published by MarketsandMarkets, the radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9%.

Courtesy of MarketsandMarkets Research

News | Radiation Dose Management | August 03, 2020
August 3, 2020 — According to the new market research report "...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
Older Americans may be receiving cancer screenings not recommended by the U.S. Preventive Services Task Force, according to Penn State College of Medicine researchers.

Getty Images

News | Radiology Imaging | July 31, 2020
July 31, 2020 — Older Americans may be receiving cancer screenings not recommended by the...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in